178 related articles for article (PubMed ID: 33550227)
1. Cost-effectiveness analysis of renal replacement therapy strategies in Guangzhou city, southern China.
Yang F; Liao M; Wang P; Liu Y
BMJ Open; 2021 Feb; 11(2):e039653. PubMed ID: 33550227
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of the Spanish renal replacement therapy program.
Villa G; Fernández-Ortiz L; Cuervo J; Rebollo P; Selgas R; González T; Arrieta J
Perit Dial Int; 2012; 32(2):192-9. PubMed ID: 21965620
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal dialysis vs. hemodialysis among patients with end-stage renal disease in Iran: which is more cost-effective?
Yousefi M; Rezaei S; Hajebrahimi S; Falsafi N; Keshvari-Shad F
BMC Nephrol; 2024 Mar; 25(1):85. PubMed ID: 38448887
[TBL] [Abstract][Full Text] [Related]
4. Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.
Zhang H; Zhang C; Zhu S; Ye H; Zhang D
BMC Health Serv Res; 2020 Feb; 20(1):122. PubMed ID: 32059726
[TBL] [Abstract][Full Text] [Related]
5. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
Wong CKH; Chen J; Fung SKS; Mok M; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
BMC Nephrol; 2020 Feb; 21(1):42. PubMed ID: 32019528
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
Yang F; Lau T; Luo N
Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
[TBL] [Abstract][Full Text] [Related]
7. Financial implications of dialysis modalities in the developing world: A Chinese perspective.
Liu J; Hutton DW; Gu Y; Hu Y; Li Y; Ma L; Zeng X; Fu P
Perit Dial Int; 2020 Mar; 40(2):193-201. PubMed ID: 32063196
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal dialysis and kidney transplant. A two-way ticket in an integrated renal replacement therapy model.
Portolés J; Moreno F; López-Sánchez P; Mancha J; Gómez M; Corchete E; Del Peso G; Bajo MA; Llópez-Carratalá R; Fernández-Perpén A;
Nefrologia; 2011; 31(4):441-8. PubMed ID: 21738247
[TBL] [Abstract][Full Text] [Related]
9. Renal replacement therapy in Latin American end-stage renal disease.
Rosa-Diez G; Gonzalez-Bedat M; Pecoits-Filho R; Marinovich S; Fernandez S; Lugon J; Poblete-Badal H; Elgueta-Miranda S; Gomez R; Cerdas-Calderon M; Almaguer-Lopez M; Freire N; Leiva-Merino R; Rodriguez G; Luna-Guerra J; Bochicchio T; Garcia-Garcia G; Cano N; Iron N; Cuero C; Cuevas D; Tapia C; Cangiano J; Rodriguez S; Gonzalez H; Duro-Garcia V
Clin Kidney J; 2014 Aug; 7(4):431-436. PubMed ID: 25349696
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of the Spanish renal replacement therapy programme.
Villa G; Rodríguez-Carmona A; Fernández-Ortiz L; Cuervo J; Rebollo P; Otero A; Arrieta J
Nephrol Dial Transplant; 2011 Nov; 26(11):3709-14. PubMed ID: 21427072
[TBL] [Abstract][Full Text] [Related]
11. Filtering for the best policy: An economic evaluation of policy options for kidney replacement coverage in the Philippines.
Bayani DBS; Almirol BJQ; Uy GDC; Taneo MJS; Danguilan RS; Arakama MI; Lamban AB; de Leon D; Pamugas GEP; Luz AC; Teerawatananon Y
Nephrology (Carlton); 2021 Feb; 26(2):170-177. PubMed ID: 33207027
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
Teerawattananon Y; Mugford M; Tangcharoensathien V
Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of increasing kidney transplantation and home-based dialysis.
Howard K; Salkeld G; White S; McDonald S; Chadban S; Craig JC; Cass A
Nephrology (Carlton); 2009 Feb; 14(1):123-32. PubMed ID: 19207859
[TBL] [Abstract][Full Text] [Related]
15. An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy.
Kontodimopoulos N; Niakas D
Health Policy; 2008 Apr; 86(1):85-96. PubMed ID: 17996975
[TBL] [Abstract][Full Text] [Related]
16. Transitions in an integrated model of renal replacement therapy in a regional health system.
Gil-Casares B; Portolés J; López-Sánchez P; Tornero F; Marques M; Rojo-Álvarez JL
Nefrologia (Engl Ed); 2022; 42(4):438-447. PubMed ID: 36266230
[TBL] [Abstract][Full Text] [Related]
17. Influence of formalized Predialysis Education Program (fPEP) on the chosen and definitive renal replacement therapy option.
Wojtaszek E; Matuszkiewicz-Rowińska J; Żebrowski P; Głogowski T; Małyszko J
Adv Clin Exp Med; 2022 Jul; 31(7):739-748. PubMed ID: 35349232
[TBL] [Abstract][Full Text] [Related]
18. Kidney transplantation and other methods of renal replacement therapy in children: 30 years of observations in one center.
Medyńska A; Kiliś-Pstrusińska K; Makulska I; Zwolińska D
Adv Clin Exp Med; 2020 May; 29(5):611-613. PubMed ID: 32469165
[TBL] [Abstract][Full Text] [Related]
19. More Use of Peritoneal Dialysis Gives Significant Savings: A Systematic Review and Health Economic Decision Model.
Pike E; Hamidi V; Ringerike T; Wisloff T; Klemp M
J Clin Med Res; 2017 Feb; 9(2):104-116. PubMed ID: 28090226
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective.
Treharne C; Liu FX; Arici M; Crowe L; Farooqui U
Appl Health Econ Health Policy; 2014 Aug; 12(4):409-20. PubMed ID: 25017433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
